$QURE

POST LEONARD E sold $54K of QURE

POST LEONARD E sold 1,993 shares of uniQure N.V. (QURE) at $27.06 on 2026-06-11.

Original reporting
SEC EDGAR · POST LEONARD E
Published Jun 12, 2026, 9:38 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$QURE
Bearish
high confidence
Mentioned
$QURE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QUREBearishLow
01

Why it matters

The newest fact is the director’s open-market sale of 1,993 shares at $27.06/share; absent other catalysts, it mainly affects sentiment/positioning rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this single small sale is unlikely to drive a sustained repricing without additional company news.

03

What to watch

The article notes no 10b5-1 plan, but the disclosed size ($53.9k) is small relative to typical institutional flows, limiting interpretive power.

Relevance 3/10Novelty 8/10Timing: filed 2026-06-12 (transaction dated 2026-06-11)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QUREBearishHigh confidence
Context

uniQure director Leonard E. Post sold 1,993 shares in an open-market transaction at $27.06/share, per a new SEC Form 4 filing.

Expected impact

Low near-term downside bias; any move is likely limited unless accompanied by other news.

Evidence & confidence

The filing is a disclosed sale (S) by a director, with no 10b5-1 plan and no accompanying company-specific operational/regulatory update in the text.

Market effects

Minimal; this is company-specific insider activity with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

Director sales can be non-informational (taxes, diversification, pre-planned liquidity needs), so the signal may be weak.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider transaction disclosure.

  • POST LEONARD E

    Director who sold 1,993 shares on 2026-06-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHigh

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

uniQure N.V. (QURE) shares rose over 20% after upgrades from Wells Fargo and RBC Capital Markets, citing improved regulatory prospects for its Huntington’s disease therapy, AMT-130. Wells Fargo raised its price target to $60, while RBC set it at $35, both noting the potential impact of an FDA official's departure. The FDA had previously requested additional trials, but analysts see a higher chance of approval.

$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.